Do we need dedicated heart failure with preserved ejection fraction clinics?
- PMID: 36988191
- DOI: 10.1093/eurheartj/ehad172
Do we need dedicated heart failure with preserved ejection fraction clinics?
Conflict of interest statement
Conflict of interest J.E.H. has received past research funding from Bayer, AG. C.S.P.L. has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc., Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai.
Comment on
-
Heart failure with preserved ejection fraction: relevance of a dedicated dyspnoea clinic.Eur Heart J. 2023 May 1;44(17):1544-1556. doi: 10.1093/eurheartj/ehad141. Eur Heart J. 2023. PMID: 36924194
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
